The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.
Complex chronic comorbidities of COPD
Open accessAbstract
Chronic obstructive pulmonary disease (COPD) is defined by fixed airflow limitation associated with an abnormal pulmonary and systemic inflammatory response of the lungs to cigarette smoke. The systemic inflammation induced by smoking may also cause chronic heart failure, metabolic syndrome and other chronic diseases, which may contribute to the clinical manifestations and natural history of COPD. Thus COPD can no longer be considered a disease only of the lungs, as it is often associated with a wide variety of systemic consequences. A better understanding of the origin and consequences of systemic inflammation, and of potential therapies, will most likely lead to better care of patients with COPD. Medical textbooks and clinical guidelines still largely ignore the fact that COPD seldom occurs in isolation. As the diagnosis and assessment of severity of COPD may be greatly affected by the presence of comorbid conditions, the current authors believe that lung function measurement, noninvasive assessment of cardiovascular and metabolic functions, and circulating inflammatory markers (e.g. C-reactive protein) might help to better characterise these patients. Similarly, preventive and therapeutic interventions should address the patient in their complexity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,528
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Self-citationCelli, B. R., MacNee, W., Agustí, A. G. N., Anzueto, A. R., Berg, B., Buist, A. S., Calverley, P. M., Chavannes, N. H., Dillard, T. A., Fahy, B. F., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,405
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
CALVERLEY, P. M. A., Anderson, J. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., Jones, P., Yates, J., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,234
Research works printed but not linked: 8
- Fabbri LM, Rabe KF. Complexity of patients with multiple chronic diseases. Proceedings of an ERS Research Seminar (Rome, February 11–12, 2007). www.ersnet.org/ers/lr/browse/default.aspx?id_dossier = 67422 Date last accessed: October 31, 2007.
- 2005, Exp Lung Res, 31, 72
- 2007, Curr Opin Pulm Med, 13, 114
- 1996, Diabetes Metab, 22, 37
- 2000, Am J Respir Crit Care Med, 161, A583
- 2006, Cardiovasc Res, 3, e333
- 2005, Cochrane Database Syst Rev, 3, CD005374
- 2007, Curr Opin Pulm Med, 13, 90
Cited by
Sorted by citations
Items 201–300 of 655
Li, H., Zeng, Z., Cheng, J., Hu, G., Li, Y., Wei, L., Zhou, Y., & Ran, P. (2020) · International Journal of COPD · doi:10.2147/copd.s231808 · Cited by 29
“Congestive heart failure (CHF) affects 20%–70% of the COPD patient population.(4,5) N-terminal pro B-type natriuretic peptide (NT-proBNP), as Correspondence: Guoping Hu Department of Respiratory Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China Te…”
BackgroundDoehner, W., von Haehling, S., Anker, S. D., & Lainščak, M. (2009) · Wiener klinische Wochenschrift · doi:10.1007/s00508-009-1194-7 · Cited by 28
“Recently, the clinical and scientific community recognized the importance of co-morbidity and particular attention is given to cardiovascular disease [22].”
BackgroundThe Risk of Erectile Dysfunction in Chronic Obstructive Pulmonary Disease
Shen, T., Chen, W., Lin, C., Chen, C., Tu, C., Hsia, T., Shih, C., Hsu, W., & Sung, F.-C. (2015) · Medicine · doi:10.1097/md.0000000000000448 · Cited by 27
“COPD, with or without comorbidity, was associated with a significantly higher risk of ED than non-COPD.”
BackgroundInfluentialMortality associated with bone fractures in COPD patients
Yamauchi, Y., Yasunaga, H., Sakamoto, Y., Hasegawa, W., Takeshima, H., Urushiyama, H., Jo, T., Matsui, H., Fushimi, K., & Nagase, T. (2016) · International Journal of COPD · doi:10.2147/copd.s112142 · Cited by 27
“2 Osteoporosis is one of the major comorbidities in COPD 3,4 and is reported to be associated with poor health status in COPD patients.”
Argano, C., Scichilone, N., Natoli, G., Nobili, A., Corazza, G. R., Mannucci, P. M., Perticone, F., Corrao, S., on behalf of the REPOSI Investigators, Mannucci, P. M., et al. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02412-1 · Cited by 27
“Aging per se is characterized by chronic low-grade systemic inflammation, and is associated with multiple chronic conditions, including COPD [2, 38, 39]; interestingly, a relationship among systemic inflammation, comorbidities and COPD outcomes has been clearly documented [40].”
Yang, K. G., Wu, Y., Chen, D., Liu, S., & Chen, R. (2020) · Clinical Epidemiology · doi:10.2147/clep.s270599 · Cited by 27
McNamara, R. J., McKeough, Z. J., McKenzie, D. K., & Alison, J. A. (2014) · Physiotherapy · doi:10.1016/j.physio.2014.09.002 · Cited by 26
Aclidinium Bromide, a Long-Acting Antimuscarinic, Does Not Affect QT Interval in Healthy Subjects
Lasseter, K. C., Aubets, J., Chuecos, F., & Gil, E. G. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374471 · Cited by 26
Beta-blocker under-use in COPD patients
Lim, K. P., Loughrey, S., Musk, M., Lavender, M. A., & Wrobel, J. P. (2017) · International Journal of COPD · doi:10.2147/copd.s144333 · Cited by 26
“%) patients on BB therapy at the time of admission were on cardioselective BBs (metoprolol 28, bisoprolol 18, atenolol 11, nebivolol 5).”
A comprehensive care plan that reduces readmissions after acute exacerbations of COPD
Ohar, J. A., Loh, C. H., Lenoir, K. M., Wells, B. J., & Peters, S. P. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.06.014 · Cited by 26
COPD Comorbidities Predict High Mortality – Asthma-COPD-Overlap Has Better Prognosis
Peltola, L., Pätsi, H., & Harju, T. H. (2020) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2020.1783647 · Cited by 26
Associations between Periodontitis and COPD: An Artificial Intelligence-Based Analysis of NHANES III
Vollmer, A., Vollmer, M., Lang, G. M., Straub, A., Shavlokhova, V., Kübler, A. C., Gubik, S., Brands, R. C., Hartmann, S., & Saravi, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237210 · Cited by 27
“An altered microbiome in the lungs has been associated with an escalation of the production of inflammatory mediators, similar to the effects of periodontitis, which have a systemic as well as a local effect [12–14].”
BackgroundApostolovic, S. R., Janković–Tomašević, R., Šalinger-Martinović, S., Djordjević-Radojković, D., Stanojević, D., Pavlović, M., Stanković, I., Putniković, B., Kafedžić, S., Catovic, S., et al. (2011) · Aging Clinical and Experimental Research · doi:10.1007/bf03337759 · Cited by 26
Chronic obstructive pulmonary disease in patients with end‐stage kidney disease on hemodialysis
Plesner, L. L., Warming, P. E., Nielsen, T. L., Dalsgaard, M., Schou, M., Høst, U., Rydahl, C., Brandi, L., Køber, L., Vestbo, J., et al. (2015) · Hemodialysis International · doi:10.1111/hdi.12342 · Cited by 26
Lee, R. N. C., Kelly, E., Nolan, G., Eigenheer, S., Boylan, D., Murphy, D., Dodd, J. D., Keane, M. P., & McNicholas, W. T. (2014) · QJM · doi:10.1093/qjmed/hcu175 · Cited by 26
Li, D., Wu, Y., Tian, P., Zhang, X., Wang, H., Wang, T., Ying, B., Wang, L., Shen, Y., & Wen, F. (2015) · Medicine · doi:10.1097/md.0000000000001503 · Cited by 26
Prevalence of airflow obstruction in patients with stable systolic heart failure
Dalsgaard, M., Plesner, L. L., Schou, M., Kjøller, E., Vestbo, J., & Iversen, K. K. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0351-9 · Cited by 25
SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD
Chen, T.-T., Wu, S., Ho, S., Chuang, H., Liu, C., Chan, Y., Kuo, L.-W., Feng, P., Liu, W., Chen, K.-Y., et al. (2017) · Scientific Reports · doi:10.1038/srep46667 · Cited by 26
“The suppressor of variegation 3–9 homolog 1, SUV39H1, is the prototype SET-domain-containing histone methyltransferase, which specifically catalyzes trimethylation on histone H3K9 (H3K9me3) and governs its global level 16,17 .”
Chindhi, S., Thakur, S., Sarkar, M. S., & Negi, P. C. (2015) · Lung India · doi:10.4103/0970-2113.152624 · Cited by 25
“[9] Low grade systemic inflammation plays the pivotal role in linking COPD with cardiovascular disease.[10] Reduced INTRODUCTION”
BackgroundBeghé, B., Verduri, A., Bottazzi, B., Stendardo, M., Fucili, A., Balduzzi, S., Leuzzi, C., Papi, A. A., Mantovani, A., Fabbri, L. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080166 · Cited by 24
“Low-grade systemic inflammation has been proposed to be the common substrate of chronic diseases such as COPD and CHF, and thus it is a possible link between these diseases and their comorbidities [4].”
BackgroundParker, K., Perikala, V., Aminazad, A., Deng, Z. H., Borg, B. M., Buchan, C., Toghill, J., Irving, L. B., Goldin, J., Charlesworth, D., et al. (2017) · Respirology · doi:10.1111/resp.13228 · Cited by 24
COPD and Associated Comorbidities: A Review of Current Diagnosis and Treatment
Carlin, B. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2582 · Cited by 24
“Integrating Management of COPD and Comorbidities Chronic obstructive pulmonary disease has systemic inflammatory effects that may contribute to other extrapulmonary disorders.(66) Major guidelines exist for the diagnosis and treatment of common comorbidities associated with COPD (Table 1).”
BackgroundCo-morbidities in patients with gold stage 4 chronic obstructive pulmonary disease
Areias, V., Carreira, S., Anciães, M., Pinto, P., & Bárbara, C. (2014) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2013.09.001 · Cited by 24
Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
Liu, S., Kuo, H., Liu, G.-H., Ho, S., Chang, H., Huang, H., Chen, Y., Huang, K., Chen, K., Fang, W., et al. (2016) · International Journal of COPD · doi:10.2147/copd.s106054 · Cited by 24
“Osteoporosis is a major comorbidity in COPD associated with poor health status and prognosis.(7,8) This risk of comorbid osteoporosis can be increased by low-grade systemic inflammation or the sequelae of COPD, such as poor nutrition, reduced physical activity, and the use of systemic corticosteroids and tobacco smoki…”
Imaizumi, Y., Eguchi, K., & Kario, K. (2014) · Pulse · doi:10.1159/000381684 · Cited by 25
Gordon, J., & Panos, R. J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003649549 · Cited by 25
“Although pulmonary derangements are the primary diagnostic and clinical manifestations, COPD is increasingly being recognized as a multisystem disorder with protean features [2-6].”
BackgroundCOPD advances in left ventricular diastolic dysfunction
Kubota, Y., Asai, K., Murai, K., Tsukada, Y. T., Hayashi, H., Saito, Y., Azuma, A., Gemma, A., & Shimizu, W. (2016) · International Journal of COPD · doi:10.2147/copd.s101082 · Cited by 22
“COPD is a systemic inflammatory disease characterized by airflow limitation that is not fully reversible.(1) COPD is complicated by a high rate of cardiac diseases(2) and is present in approximately one-third of patients with congestive heart failure (HF).”
Comorbilidades em doentes com doença pulmonar obstrutiva crónica estádio IV
Areias, V., Carreira, S., Anciães, M., Pinto, P., & Bárbara, C. (2013) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppneu.2013.02.004 · Cited by 22
“Insuficiência cardíaca congestiva (%) 4 (4,5) 4 (5,2) 0 1,0”
InfluentialInhaled corticosteroids in chronic obstructive pulmonary disease: a review
Telenga, E. D., Kerstjens, H. A. M., Postma, D. S., ten Hacken, N. H. T., & van den Berge, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903510628 · Cited by 22
“The exact mechanism linking COPD with these comorbid diseases is not yet entirely clear, although it is speculated that continuous low-grade systemic inflammation, oxidative stress or hypoxemia, and a shared genetic predisposition could play a role [56-58].”
BackgroundChronic Obstructive Pulmonary Disease
OʼReilly, S. (2016) · American Journal of Lifestyle Medicine · doi:10.1177/1559827616656593 · Cited by 23
“syndrome is seen in patients with COPD.(35) Although the exact role of these comorbidities in the mortality rates of patients with COPD is difficult to discern from that caused by the disease itself, clearly patients must be managed as those with multisystem involvement.”
BackgroundLuo, L., Zhao, S., Wang, J., Liu, Y., Zhu, Z., Xiang, Q., & Zhao, Z. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0165-4 · Cited by 22
The Big Three Concept: A Way to Tackle the Health Care Crisis?
de Verdier, M. G. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200806-058th · Cited by 22
Kita-Milczarska, K., Gawinowska, M., Chełmińska, M., & Niedoszytko, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137395 · Cited by 24
“Chronic cardiovascular disease (CVD) is a common comorbidity of COPD [266,267].”
BackgroundYohannes, A. M., Casaburi, R. H., Dryden, S., & Hanania, N. A. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106850 · Cited by 23
Rana, G. S. J. B., York, T. P., Edmiston, J. S., Zedler, B. K., Pounds, J. G., Adkins, J., Smith, R. D., Liu, Z., Li, G., Webb, B. T., et al. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3742-4 · Cited by 21
“However, peripheral blood sampling is relatively non-invasive, and COPD is increasingly recognized as a systemic inflammatory disorder with a pulmonary component [55, 56 ].”
BackgroundZhang, J., Rutten, F. H., Cramer, M. J., Lammers, J. J., Zuithoff, N. P. A., & Hoes, A. W. (2011) · Family Practice · doi:10.1093/fampra/cmr024 · Cited by 21
Kaszuba, E., Odeberg, H., Råstam, L., & Halling, A. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2008-4 · Cited by 21
“Comorbidity in patients with heart failure and COPD is well-known and widely reported [31–37].”
ResultCausas de mortalidad en la EPOC
Soriano, J. B., Almagro, P., & Sauleda, J. (2009) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(09)72857-1 · Cited by 21
Perez, T., Deslée, G., Burgel, P., Caillaud, D. M., Rouzic, O. L., Zysman, M., Escamilla, R., Jébrak, G., Chanez, P., Court‐Fortune, I., et al. (2019) · International Journal of COPD · doi:10.2147/copd.s188412 · Cited by 29
“Comorbidities are frequent in COPD, with a significant impact on symptoms, morbidity and mortality.(18) Among COPD comorbidities, cardiovascular diseases (eg, chronic heart failure [CHF] and coronary heart disease) and mood disorders (eg, depression and anxiety) could contribute to exercise limitation and then impact…”
BackgroundKoç, Ç., & Şahin, F. (2022) · Medicina · doi:10.3390/medicina58020163 · Cited by 20
β‐Blockade: Benefits Beyond Blood Pressure Reduction?
Cockcroft, J. R., & Pedersen, M. E. F. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00553.x · Cited by 20
“diabetes, coronary artery disease, HF, and CV disease (CVD) in general.(20) Since cigarette smoking is the major risk factor for”
BackgroundSoler-Lluís, N., García‐Heredia, A., Marsillach, J., Mackness, B., Mackness, M., Joven, J., Romero‐Aroca, P., & Camps, J. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-11951 · Cited by 20
Study the relationship of erythropoietin and chronic obstructive pulmonary disease
Elkorashy, R. I., Amin, Y., Moussa, H. A., Badawy, I., & Bakr, S. (2012) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2012.10.026 · Cited by 20
Extracellular Matrix Defects in Aneurysmal Fibulin-4 Mice Predispose to Lung Emphysema
Ramnath, N. W. M., van de Luijtgaarden, K. M., van der Pluijm, I., van Nimwegen, M., van Heijningen, P. M., Swagemakers, S. M. A., van Thiel, B. S., Ridwan, R. Y., van Vliet, N., Vermeij, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106054 · Cited by 20
“alveolar destruction, COPD is associated with extrapulmonary manifestations, including cardiovascular diseases [2–5].”
Temporal Trends in Hospitalization Rates for Older Adults with Chronic Obstructive Pulmonary Disease
Baillargeon, J., Wang, Y., Kuo, Y., Holmes, H. M., & Sharma, G. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.01.035 · Cited by 20
Sode, B. F., Dahl, M., & Nordestgaard, B. G. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.08.029 · Cited by 20
Salama, R., Young, P. M., Rogueda, P., Lallement, A., Iliev, I., & Traini, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.589837 · Cited by 20
“and consequently potential adverse effects on the cardiovascular system are considered not significant [39-41], although comorbidity is usually significant in patients with COPD [42].”
BackgroundMineo, D., Ambrogi, V., Lauriola, V., Pompeo, E., & Mineo, T. C. (2010) · European Respiratory Journal · doi:10.1183/09031936.00142309 · Cited by 19
Moullec, G., Laurin, C., Lavoie, K., & Ninot, G. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328343521c · Cited by 19
Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial
Donohue, J. F., Hanania, N. A., Fogarty, C. M., Campbell, S. C., Rinehart, M., & Denis-Mize, K. S. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808093934 · Cited by 19
“2007], and other controlled studies of low-dose LABA treatment for COPD have reached the same conclusion [Campbell et al. 2007; Ogale et al. 2006; Ferguson et al. 2003].”
BackgroundCOPD Heterogeneity: What This Will Mean in Practice
Rennard, S. I. (2011) · Respiratory Care · doi:10.4187/respcare.01419 · Cited by 18
Airway bacterial colonization: The missing link between COPD and cardiovascular events?
Fuschillo, S., Martucci, M., Donner, C. F., & Balzano, G. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.03.023 · Cited by 19
Enfermedad pulmonar obstructiva crónica: morbimortalidad e impacto sanitario
Gómez, J.-T., Jiménez, J. A. Q., Requena, A. H., Béjar, M. G., Gérez-Callejas, M. J., Uruñuela, M. R. Z., Vilaseca, A. M., & García, R. H. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2013.12.009 · Cited by 19
Takeda, Y., Nakanishi, K., Tachibana, I., & Kumanogoh, A. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-398313-8.00016-6 · Cited by 19
Chou, W., Lai, Y.-T., Huang, Y.-C., Chang, C.-L., Wu, W.-S., & Hung, Y. (2013) · Journal of Palliative Care · doi:10.1177/082585971302900105 · Cited by 19
Predictors of patient adherence to COPD self-management exacerbation action plans
Schrijver, J., Effing, T., Brusse-Keizer, M. G. J., van der Palen, J. A. M., VanderValk, P. D. L. P. M., & Lenferink, A. (2020) · Patient Education and Counseling · doi:10.1016/j.pec.2020.06.015 · Cited by 19
Sridhara, V. S. H. K., & Acharya, V. K. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1843823 · Cited by 18
Larney, S., Jones, N. R., Hickman, M., Nielsen, S., Ali, R. L., & Degenhardt, L. J. (2023) · Addiction · doi:10.1111/add.16178 · Cited by 18
Khedoe, P. P. S. J., de Kleijn, S., van Oeveren‐Rietdijk, A. M., Plomp, J. J., de Boer, H. C., van Pel, M., Rensen, P. C. N., Berbée, J. F. P., & Hiemstra, P. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183741 · Cited by 18
Pulmonary Rehabilitation: An Underutilized Resource in Primary COPD Care
Garvey, C. M., Fromer, L., Saver, D. F., & Yawn, B. P. (2010) · The Physician and Sportsmedicine · doi:10.3810/psm.2010.12.1825 · Cited by 18
Hunt, T., Williams, M., & Olds, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081274 · Cited by 20
“These conditions are among the more common comorbidities in people with COPD [49,50], so altering behaviour to reduce sedentary activities should be of importance in this population.”
BackgroundPark, J.-H., Lee, J., Heo, E. Y., Kim, D. K., & Chung, H. S. (2017) · International Journal of COPD · doi:10.2147/copd.s126192 · Cited by 18
“Introduction Chronic obstructive pulmonary disease (COPD) is defined as a fixed airflow limitation and is associated with a systemic inflammatory response caused by smoking.(1) Patients with COPD have numerous comorbid conditions, such as cardiovascular disease or lung cancer, which share smoking as a risk factor.”
Influence of psoriasis on circulatory system function assessed in echocardiography
Milaniuk, S., Pietrzak, A., Mosiewicz, B., Mosiewicz, J., & Reich, K. (2015) · Archives of Dermatological Research · doi:10.1007/s00403-015-1586-7 · Cited by 17
“What is more, in the logistic regression model link between psoriasis and COPD turned out to be significant after taking into consideration other factors: age, sex, socioeconomic status, smoking and obesity.”
BackgroundInfluentialDiet-induced obesity reprograms the inflammatory response of the murine lung to inhaled endotoxin
Tilton, S. C., Waters, K. M., Karin, N. J., Webb‐Robertson, B., Zangar, R. C., Lee, K. M., Bigelow, D. J., Pounds, J. G., & CORLEY, R. A. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.12.020 · Cited by 17
“with age) or hospitalization in acute situations (Fabbri et al., 2008; Perera et al., 2012).”
BackgroundErectile Dysfunction in Men with Chronic Obstructive Pulmonary Disease
Marinelli, L., Lanfranco, F., Motta, G., & Zavattaro, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122730 · Cited by 15
“Pulmonary hypertension (PAH), right ventricular dysfunction, dysrhythmia, and ischemic coronary disease are known severe consequences of COPD progression [48,49].”
BackgroundCOPD Recent Findings: Impact on Clinical Practice
Couillard, A., Muir, J. F., & Veale, D. (2010) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2010.482115 · Cited by 16
“Recent studies have shown that the prevalence of metabolic syndrome may be twice as common in COPD patients compared to healthy subjects matched for age and sex (50, 51).”
BackgroundKargın, F., Takır, H. B., Saltürk, C., Gökşenoğlu, N. Ç., Karabay, C. Y., Moçin, Ö. Y., Adıgüzel, N., Güngör, G., Balcı, M. K., Yalçınsoy, M., et al. (2014) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-9-8 · Cited by 18
“Cardiovascular diseases (CVDs), including CAD, heart failure, AF, and HT are major comorbidities in COPD [7,29,30].”
BackgroundShould pulse oximetry be included in GPs’ assessment of patients with obstructive lung disease?
Dalbak, L. G., Straand, J., & Melbye, H. (2015) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813432.2015.1117283 · Cited by 17
Woźniak, K., Śleszycka, J., Safianowska, A., Wiechno, W., & Domagala-Kulawik, J. J. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.29525 · Cited by 17
Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway
Leaker, B. R., Nicholson, G., Ali, F., Daudi, N., O’Connor, B., & Barnes, P. J. (2015) · Respiratory Research · doi:10.1186/s12931-015-0268-5 · Cited by 17
“Systemic inflammation could be an effect of the inflammation COPD mediators cause in the airways or a separate component of the disease which is independent of the processes occurring in the lungs [32, 33].”
BackgroundPrevalence of pulmonary hypertension in COPD patients living at high altitude
Aguirre-Franco, C., Torres-Duque, C. A., Salazar, G., Casas, A., Jaramillo, C., & González-García, M. (2022) · Pulmonology · doi:10.1016/j.pulmoe.2021.12.006 · Cited by 16
Alonso, J. L. I., Ramos, P. D. L., & Glez-Moro, J. M. R. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2012.05.002 · Cited by 16
The relationship between metabolic syndrome and chronic obstructive pulmonary disease
Ghatas, T. S. (2017) · Egyptian Journal of Bronchology · doi:10.4103/1687-8426.198983 · Cited by 16
Small airway remodeling in diabetic and smoking chronic obstructive pulmonary disease patients
Wu, N., Wu, Z., Sun, J., Yan, M., Wang, B., Du, X., & Liu, Y. (2020) · Aging · doi:10.18632/aging.103112 · Cited by 16
Bailey, W. C., Sciurba, F. C., Hanania, N. A., Donohue, J. F., Ferguson, G. T., Zibrak, J. D., Sharafkhaneh, A., Marcus, P., Rosa, K., Piault, E. C., et al. (2009) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2009.00032 · Cited by 16
Mahishale, V. K., Mahishale, A. V., Patil, B., Avuthu, S., & Eti, A. (2015) · Nigerian Medical Journal · doi:10.4103/0300-1652.150699 · Cited by 16
Tunsupon, P., Lal, A. A., Khamis, M. A., & Mador, M. J. (2017) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000236 · Cited by 16
“com (2) metabolic disease (diabetes, hyperlipidemia); (3) behavioral health problems (depression, anxiety, schizophrenia, bipolar disorder, posttraumatic stress disorder); (4) orthopedic problems (osteoarthritis, spinal stenosis); and (5) other diseases (peripheral vascular disease, neurologic disease, hepatic or rena…”
BackgroundZhang, Y., Xin, Q., Wu, Z. S., Wang, C., Wang, Y., Wu, Q., & Niu, R. L. (2018) · Medical Science Monitor · doi:10.12659/msm.908702 · Cited by 16
“Previous studies showed that CRP is a non-specific inflammatory marker that is elevated in coronary artery disease and obstructive lung disease [67,68].”
BackgroundEffect of lipoteichoic acid on IL-2 and IL-5 release from T lymphocytes in asthma and COPD
Mat, Z., Grensemann, B., Yakin, Y., Knobloch, J., & Koch, A. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.04.005 · Cited by 13
“In both diseases systemic inflammation might trigger comorbidities such as cachexia, lung carcinoma and chronic heart failure [1,8,9].”
BackgroundTreating the Systemic Effects of Chronic Obstructive Pulmonary Disease
Vogelmeier, C. F., & Wouters, E. F. �. (2011) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201102-020rm · Cited by 15
“Namely, that physical inactivity and obesity, which can be found in a high percentage of patients with COPD (29), may induce systemic inflammation (30, 31).”
BackgroundAlonso, J. L. I., Ramos, P. D. L., & Glez-Moro, J. M. R. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2012.02.007 · Cited by 15
Rémy, G., Dubois‐Deruy, E., Alard, J., Kervoaze, G., Chwastyniak, M., Baron, M., Beury, D., Siegwald, L., Caboche, S., Hot, D., et al. (2020) · Nutrients · doi:10.3390/nu12030827 · Cited by 16
“In the present study, we established a model of chronic co-exposure to cigarette smoke in obese and lean mice and evaluated the consequence at different organ level (lung, adipose tissues, gut, and heart), aiming at better deciphering the comorbidities [43] associated to unhealthy lifestyle in order to propose innovat…”
Yong, S. H., Leem, A. Y., Kim, Y. S., Park, M. S., Chang, J., Kim, S. U., & Jung, J. Y. (2020) · International Journal of COPD · doi:10.2147/copd.s242863 · Cited by 15
Limsuwat, C., Mankongpaisarnrung, C., Dumrongmongcolgul, N., & NUGENT, K. M. (2014) · Quality Management in Health Care · doi:10.1097/qmh.0000000000000024 · Cited by 15
Association between arterial stiffness and pulmonary function in hypertensive patients
Masugata, H., Senda, S., Okada, H., Murao, K., Inukai, M., Himoto, T., Hosomi, N., Murakami, K., Noma, T., Kohno, M., et al. (2011) · Hypertension Research · doi:10.1038/hr.2011.199 · Cited by 16
Norris, V., & Ambery, C. L. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.03.009 · Cited by 15
Health and social impacts of COPD and the problem of under-diagnosis
Carlone, S., Balbi, B., Bezzi, M., Brunori, M., Calabro, S., Barbaro, M. P. F., Micheletto, C., Privitera, S., Torchio, R., Schino, P., et al. (2014) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-9-63 · Cited by 15
“or more [39].”
The metabolic syndrome in patients with chronic obstructive pulmonary disease
Amin, N. M., Mohamed, R. S. E., Mageed, N. I. A. E., & Wahab, M. H. A. E. (2016) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2016.03.008 · Cited by 15
Aryal, S., Diaz‐Guzman, E., & Mannino, D. M. (2012) · Italian Journal of Medicine · doi:10.1016/j.itjm.2012.02.006 · Cited by 14
“Systemic inflammation in COPD is known to contribute significantly to the development of cardiovascular diseases, particularly atherosclerosis via endothelial dysfunction [27].”
BackgroundInfluentialThe treatment burden of long-term home noninvasive ventilation
Spurr, L. (2021) · Breathe · doi:10.1183/20734735.0291-2020 · Cited by 14
“Most individuals for whom domiciliary NIV is indicated have complex conditions and multimorbidity [14, 15], and are therefore highly likely to have other recommended or prescribed treatments.”
BackgroundLandi, F., Pistelli, R., Abbatecola, A. M., Barillaro, C., Brandi, V., & Lattanzio, F. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000410745.75216.99 · Cited by 15
Ambrosino, N., & Paggiaro, P. (2012) · Expert Review of Respiratory Medicine · doi:10.1586/ers.12.2 · Cited by 14
Dar, S. A., Bhat, B. A., Shah, N. N., & Imtiyaz, S. (2018) · Journal of Neurosciences in Rural Practice · doi:10.4103/jnrp.jnrp_244_18 · Cited by 15
“[16,17] Depression is a highly prevalent comorbidity in patients with COPD and its other associated negative aspects in the course of the disease.”
Berkhof, Metzemaekers, L., Uil, S. M., Kerstjens, H. A. M., & van den Berg, J. W. (2014) · International Journal of COPD · doi:10.2147/copd.s66028 · Cited by 14
“including an increased prevalence of cardiovascular disease in comparison with the general population.(2) Nine percent to 41% of COPD patients have heart failure (HF).”
Anticholinergic Drugs for the Treatment of COPD Are Safe… Are They?
Rabe, K. F. (2010) · CHEST Journal · doi:10.1378/chest.09-2466 · Cited by 14
Systemic Inflammation in Chronic Obstructive Pulmonary Disease: May Diet Play a Therapeutic Role?
Toraldo, D. M., Nuccio, F. D., & Scoditti, E. (2011) · Journal of Allergy & Therapy · doi:10.4172/2155-6121.s2-005 · Cited by 16
“A question arises whether systemic inflammation is the result of a local inflammation spill-over of the lung to the systemic compartments or a systemic component of COPD, not necessarily related to the local inflammatory processes in the lung [6,7].”
BackgroundMulti Feature fusion for COPD Classification using Deep learning algorithms
Patel, P. J., Diwan, D., Patel, K. A., Ranga, S. V., Modi, N. J., & Dumasia, S. (2024) · Journal of Integrated Science and Technology · doi:10.62110/sciencein.jist.2024.v12.780 · Cited by 13
Tao, L., Zhang, Q., Liu, L., Wang, K., Liu, X., Li, J., & Zhao, P. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119068 · Cited by 14
Esquivel-Campos, A. L., Pérez‐Ramos, J., Cisneros, J., Herrera, I., Rivera-Rosales, R. M., Montaño, M., & Ramos, C. (2014) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2014.956911 · Cited by 13
“Tobacco constitutes the foremost cause of chronic inflammation of the airways in smokers, which persists even after smoking cessation (Fabbri et al., 2008; GOLD, 2014; Vijayan, 2013).”
BackgroundYoshimi, K., Oh, S., Suzuki, K., Kodama, Y., Sekiya, M., Seyama, K., & Fukuchi, Y. (2016) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.15-00301 · Cited by 13
Metadata
- Authors
- Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2007-12-31
- Volume
- 31
- Issue
- 1
- Pages
- 204-212
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2165340553
- Cited by
- 660
- References
- 139
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 20 · 2023: 17 · 2022: 26 · 2021: 19 · 2020: 35 · 2019: 25 · 2018: 36 · 2017: 48 · 2016: 31 · 2015: 50 · 2014: 68 · 2013: 55 · 2012: 59
- FWCI
- 28.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- chronic obstructive pulmonary disease, comorbidities, systemic inflammation, chronic heart failure, metabolic syndrome, cigarette smoking, C-reactive protein, inflammatory markers, COPD severity assessment, cardiovascular function, COPD management
- MeSH terms
- Chronic Disease, Health Status, Humans, Inflammation, Lung, Models, Biological, Prognosis, Risk Factors, Smoking, Pulmonary Medicine, Comorbidity, Guidelines as Topic, Pulmonary Disease, Chronic Obstructive, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
